The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 55 | — | 20.1x | Near average | |
Growth | 74 | — | 5.6% | Above average | |
Quality | 9 | -105.2% | 7.6% | Below average | |
Safety | 78 | 0.1x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Relmada Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Relmada Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Relmada stock shows a state of complete stability in price targets over the past 30 days, with the average price target stabilizing at 9 dollars. However, the data reflects a weakness in analyst coverage, as the current consensus relies on only one analyst, which increases concentration risk and reduces the reliability of statistical dispersion among different opinions. The gap between the current price (7.04) and the target (9) indicates theoretical optimism for potential growth, but it is not supported by momentum from new analyst reviews.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.